Articles related to MENTAL HEALTH

The combined analysis showed that therapist-led CBT, lisdexamfetamine, SGAs, and topiramate reduced binge eating and related obsessions and compulsions. Lisdexamfetamine and topiramate reduced weight. SGAs reduced symptoms of depression.

This brief editorial introduces a series of articles describing the medical use of hallucinogens, ketamine, marijuana, and other agents — including the legal and ethical perspectives — in the treatment of various neurologic and psychiatric disorders.

The 8-week treatment with mindfulness-based stress reduction was a well-tolerated treatment option with comparable effectiveness to a first-line medication for patients with anxiety disorders in this randomized clinical trial of 276 adults with anxiety disorders.

This article provides a brief review of three important books on the thinking and experience around psychedelics in medicine: The Promise of Psychedelics, by Peter Silverstone, MD; Psychedelic Medicine, by Richard Louis Miller, MA, PhD; How to Change Your Mind, by Michael Pollan.

After supporting a number of significant clinical trials in psychiatry more than ten years ago, NIMH abruptly shifted its approach and began allocating 90% of its money to neuroscience. The policy is still in place even though this “has yet to deliver major clinical gains.” Clinical advancement has been halted as a result of the devaluation of mental clinical trials and the meticulously designed, essential methodologies they demand.

This review of three recent publications in Schizophrenia Bulletin, Expert Opinion in Pharmacotherapy, and Frontiers in Psychiatry highlights some potential opportunity to change standard practice and improve patient outcomes. Emerging research indicates that once-daily dosing before bed is likely effective, reduces adverse effects, and boosts adherence. Furthermore, when switching agents, immediate discontinuation may be preferable, with no need to taper.